Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 1/20 | 0.49 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | CASR | P41180 | 1/20 | 0.45 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.41 |
| ▸ | HTR7 | P34969 | 4/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.40 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.38 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12881927 | 0.81 | AOC3 (0.50) | AOC3CYP2A6CASRFFAR1LIPG | |
| SCHEMBL3643354 | 0.81 | AOC3 (0.52) | AOC3CYP2A6CASRFFAR1LIPG | |
| SCHEMBL12866833 | 0.80 | DRD2 (0.48) | CASRFFAR1LIPGHTR7PDK2 | |
| SCHEMBL197793 | 0.80 | GGPS1 (0.44) | — | |
| SCHEMBL14402479 | 0.79 | AOC3 (0.48) | AOC3CYP2A6CASRFFAR1LIPG | |
| SCHEMBL20781840 | 0.78 | CSNK2A1 (0.62) | CYP2A6HTR7MAOB | |
| SCHEMBL12866818 | 0.78 | HTR7 (0.64) | CYP2A6CASRFFAR1HTR7 | |
| SCHEMBL12866839 | 0.78 | SCN9A (0.47) | FFAR1HTR7CLK4ARSCN9A | |
| SCHEMBL14402842 | 0.78 | HSD11B1 (0.52) | AOC3CYP2A6CASRFFAR1LIPG | |
| SCHEMBL18014701 | 0.77 | TAAR1 (0.50) | AOC3MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3052495-B1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2019-06-26 | — | — | EP | disclosed |
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | PFIZER (US) | 2016-08-11 | — | — | US | disclosed |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | PFIZER, INC. | 2011-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160229847-A1 | NOVEL BICYCLIC PYRIDINONES AS GAMMA-SECRETASE MODULATORS | BACE1, BACE2, PSEN2 | AOC3 4031/4885CYP2A6 776/4885CASR 1904/4885 |
| US-20110046160-A1 | Novel Class of Spiro Piperidines for the Treatment of Neurodegenerative Diseases | SNCA, PARK7, HTT | AOC3 2004/4885CYP2A6 1530/4885CASR 4186/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.